BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Phase 3

Completed

Conditions: Deep Vein Thrombosis

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Unfractionated heparin
Drug: Warfarin

First Posted Date: 2012-01-25

Last Posted Date: 2017-01-18

Lead Sponsor: Bayer

Target Recruit Count: 60

Registration Number: NCT01516840

Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate

Phase 3

Completed

Conditions: Hyperphosphatemia

Interventions: Drug: Lanthanum carbonate (BAY77-1931)
Drug: Calcium carbonate

First Posted Date: 2012-01-23

Last Posted Date: 2012-06-08

Lead Sponsor: Bayer

Target Recruit Count: 259

Registration Number: NCT01514851

Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)

Phase 3

Completed

Conditions: Macular Edema

Interventions: Biological: VEGF Trap-Eye (BAY86-5321)

First Posted Date: 2012-01-20

Last Posted Date: 2014-10-09

Lead Sponsor: Bayer

Target Recruit Count: 73

Registration Number: NCT01512966

Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Sorafenib (Nexavar, BAY 43-9006)

First Posted Date: 2012-01-12

Last Posted Date: 2015-01-21

Lead Sponsor: Bayer

Target Recruit Count: 20

Registration Number: NCT01508364

Switching Study From Warfarin to Rivaroxaban

Phase 1

Completed

Conditions: Venous Thrombosis

Interventions: Drug: Warfarin (Coumadin)
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Placebo
Drug: Vitamin K (Konakion)

First Posted Date: 2012-01-10

Last Posted Date: 2015-02-09

Lead Sponsor: Bayer

Target Recruit Count: 96

Registration Number: NCT01507051

Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain

Phase 3

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Naproxen Sodium 440 mg (BAYH6689)
Drug: DPH 50 mg
Drug: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)

First Posted Date: 2011-12-20

Last Posted Date: 2015-06-08

Lead Sponsor: Bayer

Target Recruit Count: 267

Registration Number: NCT01495858

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

First Posted Date: 2011-12-13

Last Posted Date: 2018-04-05

Lead Sponsor: Bayer

Target Recruit Count: 1085

Registration Number: NCT01491100

Myocardial Perfusion MRI

Phase 2

Completed

Conditions: Magnetic Resonance Imaging
Myocardial Perfusion Imaging

Interventions: Drug: Gadobutrol (Gadavist,Gadovist, BAY86-4875)

First Posted Date: 2011-12-12

Last Posted Date: 2014-05-22

Lead Sponsor: Bayer

Target Recruit Count: 232

Registration Number: NCT01490294

Relative Bioavailability and Food Effect Study

Phase 1

Completed

Conditions: Pharmacology, Clinical

Interventions: Drug: Riociguat (BAY63-2521)

First Posted Date: 2011-12-09

Last Posted Date: 2015-07-01

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT01489488

VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)

Phase 3

Completed

Conditions: Macular Degeneration

Interventions: Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Drug: Visudyne

First Posted Date: 2011-12-01

Last Posted Date: 2016-11-04

Lead Sponsor: Bayer

Target Recruit Count: 304

Registration Number: NCT01482910

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy